α-干扰素治疗慢性病毒性肝炎的不良反应及其临床干预方法

刘佳

（陕西省西安市第九医院感染科，陕西 西安，710054）

浏览次数：75次 下载次数：432次

摘要：

目的 研究α-干扰素在治疗慢性病毒性肝炎中的副作用及相应的干预方法。方法 选择2013年6月至2015年6月本院收治的慢性病毒性肝炎患者212例，随机分为观察组和对照组，每组106例。观察组使用聚乙二醇干扰素治疗，对照组使用普通干扰素治疗，治疗12个月，对比两组患者的血小板、中性粒细胞、白细胞的变化及差异，以及两组患者的不良反应。结果 观察组患者的血小板、白细胞下降率高于对照组患者（P<0.05）；两组患者中性粒细胞下降率比较，差异不显著（P>0.05）。 198例中性粒细胞减少的患者的不良反应发生率为1.52%；66例血小板减少的患者的不良发应发生率为3.03%。结论 聚乙 二醇干扰素比普通干扰素更易造成骨髓抑制的不良反应，而白细胞下降幅度可用作对干扰素治疗效果的预测。

关键词：α-干扰素；慢性病毒性肝炎；临床干预

中图分类号：R575.1文献标志码：A文章编号：2096-1413(2017)22-0023-02

Adverse reactions of interferon alpha in the treatment of chronic viral hepatitis and its clinical intervention
LIU Jia
(Department of Infectious Disease, the Ninth Hospital of Xi``an, Xi``an 710054, China)

ABSTRACT: Objective To study the adverse reactions of interferon alpha in the treatment of chronic viral hepatitis and its clinical intervention. Methods From June 2013 to June 2015, 212 patients with chronic viral hepatitis admitted in our hospital were randomly divided into observation group and control group, with 106 cases in each group. The observation group was treated with pegylated interferons, and the control group was treated with normal interferon. After 12 months treatment, the changes of platelets, neutrophils, leukocytes and adverse reactions in the two groups were compared. Results The decrease rate of platelets and WBC in the observation group were higher than those in the control group (P<0.05). There was no significant difference in the rate of neutrophil decline between the two groups (P>0.05). The adverse reactions rate in neutropenia occurred of 198 cases was 1.52% , and the adverse reactions rate in thrombocytopenia of 66 cases was 3.03%. Conclusion Pegylated interferons is more likely to cause adverse effects of bone marrow suppression than normal interferon, and the range of white blood cell decline can be used to predict the efficacy of interferon treatment.
KEYWORDS: alpha-interferon; chronic viral hepatitis; clinical intervention

参考文献：
[1] 刘平,慕永平,刘成海.中医药治疗慢性肝病的临床与基础研究进展[J].临床肝胆病杂志,2011,27(5):451-457.
[2] 张艳.聚乙二醇干扰素α-2a 联合利巴韦林治疗慢性病毒性丙型肝炎的效果及护理[J].现代临床护理,2011,10(7):45-47.
[3] 刘丽,王政慧,李春荣.长效干扰素皮下注射后皮肤副反应的护理干预[J].中国临床研究,2011,24(10):950.
[4] 彭韫丽.干扰素联合拉米夫定治疗慢性乙型肝炎的疗效观察和护理[J].黑龙江医药,2014,27(2):448-450.
[5] 韩津萍.护理干预提高干扰素治疗慢性丙型肝炎患者依从性及自我管理能力[J].青岛医药卫生,2013,45(5):374-375.
[6] 魏红梅,甘凯.干扰素治疗180 例丙肝患者的临床药物副作用护理体会[J].大家健康:学术版,2014,10(23):282-283.
[7] 张春梅,刘涛.乙型病毒性肝炎的治疗进展与展望[J].牡丹江医学院学报,2015,36(1):87-91.
[8] 黄德东,朱飞燕,王少扬.吲哚美辛防治干扰素联合利巴韦林治疗慢性丙型肝炎所致流感样症候群[J].肝脏,2015,20(4):326-329.
[9] 赵静.整体护理对干扰素治疗肝炎致精神及神经系统不良反应的效果观察[J].实用临床医药杂志,2015,19(18):52-54,61.
[10] 谢绍武.中医药治疗慢性乙型肝炎肝纤维化研究进展[J].中医药临床杂志,2012,24(12):1235-1239.